| Strength: | |
|---|---|
| Quantity: | |
Brief Introduction:
National Medical Insurance, Category B.
Launched in 2016.
1st 40kD Y-shape branched PEG modified interferon alfa-2b injection in the world.
National class 1 new drug, therapeutic biological products.
Indications:
Chronic hepatitis B. For details, please refer to Instructions.
Clinical Cure of Chronic Hepatitis B
To be the leader in CHB clinical cure based on pegylated interferon alfa-2b
*Exploratory clinical research, improve CHB clinical cure level
Recently, Amoytop Biotech has supported many exploratory studies of combination regimen with pegylated interferonalfa and nucleos(t)ide analogues (NAs) on CHB clinical cure conducted by top domestic hepatitis experts, including Anchor study, ICURE study, etc.. Besides, Amoytop Biotech has supported 5 research subjects involved in the National Major Scientific and Technological Projects on "Prevention and Treatment of Major Infectious Diseases of AIDS and Viral Hepatitis"during the 13th Five-Year Plan period, which are also exploratory studies focusing on the clinical cure of chronic hepatitis B.
* Clinical study of CHB clinical cure, the 1stconfirmatory clinical study with clinical cure as treatment target in CHB treatment fields
The confirmatory clinical study of combination treatment of pegylated interferon alfa-2b injection (Pegbing) and NAs in NAs-experienced CHB patients is approved for implementing in China, meanwhile observation research in treatment-naive CHB patients is also approved, which will provide high-level medical evidence for rational drug use and treatment optimization on CHB. This is a multi-center, randomized, controlled and confirmatory clinical study to evaluate the efficacy of combinationt treatment of Pegbing and NAs in CHB patients (HBsAg positive for at least 6 months or with other CHB diagnosis evidence) with clinical cure rate (undetectable serum HBsAg) as primary efficacy parameter. It is planned to include 400 CHB patients, including 240 cases of NA-experienced patients with HBsAg< 1500IU/ml and HBV DNA < 100IU/ml and 100 cases of CHB treatment-native patients with HBV DNA≥ 10000IU/ml.
Academic progress
Guidance Interpretation | Professor Wang Guiqiang: Main updates in the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 edition)” and the value of PEG-IFN-alfa in CHB treatment
2020-03-18
Consensus Interpretation | Professor Ning Qin: Interpret“The expert consensus on clinical cure (functional cure) of chronic hepatitis B”--2019 Chinese version and English version
2020-03-18
[Global Progress] The US NIH released a Strategic Plan For Trans-NIH Research To Cure Hepatitis B
2020-03-18
Global virus outbreaks: Interferons as 1st responders
2020-03-12
Why interferon-alfa can be used for the treatment of novel coronavirus disease?
2020-03-12
Brief Introduction:
National Medical Insurance, Category B.
Launched in 2016.
1st 40kD Y-shape branched PEG modified interferon alfa-2b injection in the world.
National class 1 new drug, therapeutic biological products.
Indications:
Chronic hepatitis B. For details, please refer to Instructions.
Clinical Cure of Chronic Hepatitis B
To be the leader in CHB clinical cure based on pegylated interferon alfa-2b
*Exploratory clinical research, improve CHB clinical cure level
Recently, Amoytop Biotech has supported many exploratory studies of combination regimen with pegylated interferonalfa and nucleos(t)ide analogues (NAs) on CHB clinical cure conducted by top domestic hepatitis experts, including Anchor study, ICURE study, etc.. Besides, Amoytop Biotech has supported 5 research subjects involved in the National Major Scientific and Technological Projects on "Prevention and Treatment of Major Infectious Diseases of AIDS and Viral Hepatitis"during the 13th Five-Year Plan period, which are also exploratory studies focusing on the clinical cure of chronic hepatitis B.
* Clinical study of CHB clinical cure, the 1stconfirmatory clinical study with clinical cure as treatment target in CHB treatment fields
The confirmatory clinical study of combination treatment of pegylated interferon alfa-2b injection (Pegbing) and NAs in NAs-experienced CHB patients is approved for implementing in China, meanwhile observation research in treatment-naive CHB patients is also approved, which will provide high-level medical evidence for rational drug use and treatment optimization on CHB. This is a multi-center, randomized, controlled and confirmatory clinical study to evaluate the efficacy of combinationt treatment of Pegbing and NAs in CHB patients (HBsAg positive for at least 6 months or with other CHB diagnosis evidence) with clinical cure rate (undetectable serum HBsAg) as primary efficacy parameter. It is planned to include 400 CHB patients, including 240 cases of NA-experienced patients with HBsAg< 1500IU/ml and HBV DNA < 100IU/ml and 100 cases of CHB treatment-native patients with HBV DNA≥ 10000IU/ml.
Academic progress
Guidance Interpretation | Professor Wang Guiqiang: Main updates in the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 edition)” and the value of PEG-IFN-alfa in CHB treatment
2020-03-18
Consensus Interpretation | Professor Ning Qin: Interpret“The expert consensus on clinical cure (functional cure) of chronic hepatitis B”--2019 Chinese version and English version
2020-03-18
[Global Progress] The US NIH released a Strategic Plan For Trans-NIH Research To Cure Hepatitis B
2020-03-18
Global virus outbreaks: Interferons as 1st responders
2020-03-12
Why interferon-alfa can be used for the treatment of novel coronavirus disease?
2020-03-12
